

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucanabiomed.com W: www.nucanabiomed.com

NuCana Appoints Erwan Lejeune as Scientific Affairs Manager

NuCana BioMed ('NuCana') announced today the appointment of Erwan Lejeune, PhD as Scientific Affairs Manager. Erwan brings to NuCana nearly 10 years of project management experience, and a specific expertise in the area of cancer research. During his career he successfully developed and led several scientific projects of international scale in Australia, Germany and Japan.

"At such an important stage of our development, generating outstanding clinical results, Erwan brings strong scientific backing and project leadership skills to NuCana" commented Hugh Griffith, CEO. "With his right blend of technical and management expertise I fully expect he will be a major contributor to our growing success."

NuCana has entered the clinic with its first ProTide molecule NUC-1031, which is already producing impressive results. Building on this success, NuCana aims to rapidly bring its large pipeline of anti-cancer agents through development to commercialisation. Several additional ProTides are currently at late stage non clinical development and will enter the clinic in 2014.

"I am honoured to join such an experienced, high-caliber team," said Erwan Lejeune "I look forward to taking on my role as Scientific Affairs Manager of NuCana, one of the most innovative biotech companies in the oncology setting."

Erwan Lejeune is a Saltire Fellow. He holds his PhD in Biology from the world-class EMBL European research institute in Germany and was a Marie Curie post-doctoral fellow at the Wellcome Trust Centre in Edinburgh. Erwan built his business acumen at the top executive MBA program from Babson College in Boston.

About NuCana BioMed

Headquartered in Edinburgh, UK, NuCana BioMed is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.